Publikationen in Zusammenarbeit mit Forschern von Wakayama Medical University (1)

2018

  1. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. e465-e479